Themis Medicare launches novel Opioid Injectable Analgesic ‘Remifentanil’

10 Nov 2023 Evaluate

Themis Medicare has launched a novel Opioid Injectable Analgesic Remifentanil under its brand name Remithem in the Indian market for use during induction of anesthesia, during immediate post operative period and in monitored anesthesia care. 

Remifentanil was first approved in USA in 1996 and has wide clinical usage & acceptance around the world in major markets including USA, Europe, Japan and other countries and is also well published. The company has done pioneering work by conducting phase III trials at 13 centers in India before getting Remifentanil approved by the regulators. Remithem Remifentanil is considered to be a Dial In Opioid Analgesic as it has a quick onset of action, while it also has a very short context sensitive half-life enabling in addition a quick offset of action, while reducing the overall time in the OT and Post operative care room.

Themis Medicare is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives.


Themis Medicare Share Price

105.60 -0.70 (-0.66%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×